Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines reports developments for a central nervous system precision neuroscience biopharmaceutical company focused on therapies for disorders involving neuronal excitation-inhibition imbalance. Its recurring updates cover the Cerebrum small molecule platform, the Solidus antisense oligonucleotide platform, and product candidates across movement disorders and epilepsy, including ulixacaltamide, relutrigine, vormatrigine and elsunersen.
Company news commonly addresses FDA review activity, clinical trial data, scientific presentations, operating and financial results, commercial-readiness updates, equity inducement grants under Nasdaq rules and governance matters. Disease areas highlighted in its disclosures include essential tremor and developmental and epileptic encephalopathies associated with SCN2A and SCN8A.
Praxis Precision Medicines (NASDAQ: PRAX) announced the pricing of its upsized IPO, offering 10 million shares at $19.00 each, aiming for gross proceeds of approximately $190 million. The shares will start trading on the Nasdaq on October 16, 2020, with the offering expected to close on October 20, 2020, subject to customary closing conditions. Underwriters include Cowen, Evercore ISI, and Piper Sandler, with an option for an additional 1.5 million shares. The company focuses on developing therapies for central nervous system disorders.